In order to ensure the safety of vaccines produced on avian cells, rigorous testing for the absence of avian retroviruses must be performed. Current methods used to detect avian retroviruses often exhibit a high invalid-test/false-positive rate, rely on hardto-secure reagents, and/or have readouts that are difficult to standardize. Herein, we describe the development and validation of two consistent and sensitive methods for the detection of avian retroviruses in vaccines: viral amplification on DF-1 cells followed by immunostaining for the detection of avian leukosis virus (ALV) and viral amplification on DF-1 cells followed by fluorescent product-enhanced reverse transcriptase (F-PERT) for the detection of all avian retroviruses. Both assays share an infectivity stage on DF-1 cells followed by a different endpoint readout depending on the retrovirus to be detected. Validation studies demonstrated a limit of detection of one 50% cell culture infectious dose (CCID 50 )/ml for retrovirus in a 30-ml test inoculum volume for both methods, which was as sensitive as a classical method used in the vaccine industry, namely, viral amplification on primary chicken embryo fibroblasts followed by the complement fixation test for avian leukosis virus (COFAL). Furthermore, viral amplification on DF-1 cells followed by either immunostaining or F-PERT demonstrated a sensitivity that exceeds the regulatory requirements for detection of ALV strains. A head-to-head comparison of the two endpoint methods showed that viral amplification on DF-1 cells followed by F-PERT is a suitable method to be used as a stand-alone test to ensure that vaccine preparations are free from infectious avian retroviruses.V accines are very effective at reducing death and suffering caused by viral diseases. Many vaccines are generated on primary avian cells, such as the vaccines for yellow fever, measles, and mumps. International health authorities require vaccines produced on avian cells to be tested for and demonstrated to be free of infectious avian retroviruses such as avian leukosis virus (ALV) and reticuloendotheliosis virus (REV) (1, 2, 3, 4). For example, detailed regulatory requirements are outlined specifically for the detection of ALV and REV in the European Pharmacopeia (Ph. Eur.) (2). Furthermore, the detection of reverse transcriptase (RT) activity, which is indicative of the presence of retroviruses, by highly sensitive PCR-based methods is recommended by several international regulatory authorities (3, 4, 5).The detection of RT activity in yellow fever, measles, and mumps vaccines (6, 7) clearly demonstrated a need for effective methods to test for the presence of replication-competent retroviral contaminants. It was discovered upon further investigation that nonreplicative endogenous avian retroviral elements not associated with infectious retroviruses were responsible for the positive RT signals observed in these vaccines (8,9,10,11,12). As a consequence, it is now understood that it is necessary to test for the presence of infectious ...